Abstract Radiation pneumonitis (RP) is the most common adverse event of thoracic radiotherapy, which primarily occurs within the 3 months after the beginning of radiotherapy. RP can not only negatively affect the pulmonary function and quality of life of patients, but also limit the prescribed dose and the implementation of radiotherapy plan, lower the radiotherapy efficacy and even lead to death. Currently, multiple studies have been conducted to explore the predictive factors of RP. In this article, clinical predictive factors including dosimetric parameters, peripheral blood cells along with cytokines and pulmonary function parameters were classified and illustrated, aiming to provide valuable predictive indicators for clinical use and reduce the incidence of RP.
Wang Sheng,Wang Cailian. Research progress on clinical factors for predicting radiation pneumonitis[J]. Chinese Journal of Radiation Oncology, 2021, 30(3): 305-310.
Wang Sheng,Wang Cailian. Research progress on clinical factors for predicting radiation pneumonitis[J]. Chinese Journal of Radiation Oncology, 2021, 30(3): 305-310.
[1] Common Terminology Criteria for Adverse Events (CTCAE)[DB/OL] [2020-06-02].https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. [2] Palma DA,Senan S,Tsujino K,et al.Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:an international individual patient data meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):444-450.DOI:10.1016/j.ijrobp.2012.04.043. [3] Marks LB,Yu X,Vujaskovic Z,et al.Radiation-induced lung injury[J].Semin Radiat Oncol,2003,13(3):333-345.DOI:10.1016/S1053-4296(03)00034-1. [4] Castillo R,Pham N,Castillo E,et al.Pre-radiation therapy fluorine 18 fluorodeoxyglucose PET helps identify patients with esophageal cancer at high risk for radiation pneumonitis[J].Radiology,2015,275(3):822-831.DOI:10.1148/radiol.14140457. [5] Tsoutsou PG,Koukourakis MI.Radiation pneumonitis and fibrosis:mechanisms underlying its pathogenesis and implications for future research[J].Int J Radiat Oncol Biol Phys,2006,66(5):1281-1293.DOI:10.1016/j.ijrobp.2006.08.058. [6] Stenmark MH,Cai XW,Shedden K,et al.Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy[J].Int J Radiat Oncol Biol Phys,2012,84(2):e217-e222.DOI:10.1016/j.ijrobp.2012.03.067. [7] Jain V,Berman AT.Radiation pneumonitis:old problem,new tricks[J].Cancers (Basel),2018,10(7):222.DOI:10.3390/cancers10070222. [8] Dhami G,Zeng J,Vesselle HJ,et al.Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry[J].Strahlenther Onkol,2017,193(5):410-418.DOI:10.1007/s00066-017-1114-0. [9] Yorke ED,Jackson A,Rosenzsweig KE,et al.Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy[J].Int J Radiat Oncol Biol Phys,2002,54(2):329-339.DOI:10.1016/s0360-3016(02)02929-2. [10] Katsui K,Ogata T,Watanabe K,et al.Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer:a retrospective analysis[J].BMC Cancer,2019,19(1):1144.DOI:10.1186/s12885-019-6359-9. [11] Cho WK,Oh D,Kim HK,et al.Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery[J].Radiother Oncol,2019,133(1):87-92.DOI:10.1016/j.radonc.2019.01.005. [12] Ricardi U,Filippi AR,Guarneri A,et al.Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy[J].Acta Oncol,2009,48(4):571-577.DOI:10.1080/02841860802520821. [13] Matsuo Y,Shibuya K,Nakamura M,et al.Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer[J].Int J Radiat Oncol Biol Phys,2012,83(4):e545-e549.DOI:10.1016/j.ijrobp.2012.01.018. [14] Palma DA,Senan S,Tsujino K,et al.Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:An international individual patient data meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):444-450.DOI:10.1016/j.ijrobp.2012.04.043. [15] Roeder F,Friedrich J,Timke C,et al.Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer[J].Strahlenther Onkol,2010,186(3):149-156.DOI:10.1007/s00066-010-2018-4. [16] 孙帅,陈辛元,王静波,等.256例局部晚期NSCLC调强放疗后放射性肺损伤预测因素分析[J].中华放射肿瘤学杂志,2015,24(5):479-483.DOI:10.3760/cma.j.issn.1004-4221.2015.05.001. Sun S,Chen XY,Wang JB,et al.Predictive factors for radiation-induced lung injury in locally advanced non-small cell lung cancer after intensity-modulated radiotherapy[J].Chin J Radiat Oncol,2015,24(5):479-483.DOI:10.3760/cma.j.issn.1004-4221.2015.05.001. [17] Nakamura M,Nishimura H,Nakayama M,et al.Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer[J].Br J Radiol,2016,89(1068):20160560.DOI:10.1259/bjr.20160560. [18] Tekatli H,Tetar S,Warner A,et al.197PD:identifying dosimetric predictors of toxicity in multiple lung tumors treated with stereotactic ablative radiotherapy (SABR)[J].J Thorac Oncol,2016,11(4):S143.DOI:10.1016/S1556-0864(16)30306-9. [19] Bongers EM,Botticella A,Palma DA,et al.Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs[J].Radiother Oncol,2013,109(1):95-99.DOI:10.1016/j.radonc.2013.10.011. [20] 王谨,庄婷婷,何智纯,等.非小细胞肺癌同期放化疗后重度急性放射性肺炎的预测因素[J].中华放射肿瘤学杂志,2012,21(4):326-329.DOI:10.3760/cma.j.issn.1004-4221.2012.04.011. Wang J,Zhuang TT,He ZC,et al.Severe acute radiation pneumonitis after concurrent chemoradiotherapy in non-small cell lung cancer[J].Chin J Radiat Oncol,2012,21(4):326-329.DOI:10.3760/cma.j.issn.1004-4221.2012.04.011. [21] Ryckman JM,Baine M,Carmicheal J,et al.Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy[J].Radiat Oncol,2020,15(1):33.DOI:10.1186/s13014-020-1479-6. [22] Lu C,Lei Z,Wu HB,et al.Evaluating risk factors of radiation pneumonitis after stereotactic body radiation therapy in lung tumor:Meta-analysis of 9 observational studies[J].PLoS One,2018,13(12):e0208637.DOI:10.1371/journal.pone.0208637. [23] Tekatli H,Duijm M,Oomen-de Hoop E,et al.Normal tissue complication probability modeling of pulmonary toxicity after stereotactic and hypofractionated radiation therapy for central lung tumors[J].Int J Radiat Oncol Biol Phys,2018,100(3):738-747.DOI:10.1016/j.ijrobp.2017.11.022. [24] Kim K,Lee J,Cho Y,et al.Predictive factors of symptomatic radiation pneumonitis in primary and metastatic lung tumors treated with stereotactic ablative body radiotherapy[J].Radiat Oncol J,2017,35(2):163-171.DOI:10.3857/roj.2017.00066. [25] Baker R,Han G,Sarangkasiri S,et al.Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung[J].Int J Radiat Oncol Biol Phys,2013,85(1):190-195.DOI:10.1016/j.ijrobp.2012.03.041. [26] 冯潇,葛红,程志垚,等.SPECT肺灌注显像在优化NSCLC放疗计划中的价值[J].中华放射肿瘤学杂志,2017,26(3):287-290.DOI:10.3760/cma.j.issn.1004-4221.2017.03.008. Feng X,Ge H,Cheng ZY,et al.Value of single-photon emission computed tomography perfusion lung scintigraphy in radiotherapy optimization for non-small cell lung cancer[J].Chin J Radiat Oncol,2017,26(3):287-290.DOI:10.3760/cma.j.issn.1004-4221.2017.03.008. [27] Dhami G,Zeng J,Vesselle HJ,et al.Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry[J].Strahlenther Onkol,2017,193(5):410-418.DOI:10.1007/s00066-017-1114-0. [28] Lee HJ Jr,Zeng J,Vesselle HJ,et al.Correlation of functional lung heterogeneity and dosimetry to radiation pneumonitis using perfusion SPECT/CT and FDG PET/CT imaging[J].Int J Radiat Oncol Biol Phys,2018,102(4):1255-1264.DOI:10.1016/j.ijrobp.2018.05.051. [29] Kong FM,Ten Haken R,Eisbrunch A,et al.Non-small cell lung cancer therapy-related pulmonary toxicity:an update on radiation pneumonitis and fibrosis[J].Semin Oncol,2005,32(2suppl 3):S42-S54.DOI:10.1053/j.seminoncol.2005.03.009. [30] S N SG,Raviraj R,Nagarajan D,et al.Radiation-induced lung injury:impact on macrophage dysregulation and lipid alteration-a review[J].Immunopharmacol Immunotoxicol,2019,41(3):370-379.DOI:10.1080/08923973.2018.1533025. [31] Chang SH.T helper 17(Th17) cells and interleukin-17(IL-17) in cancer[J].Arch Pharm Res,2019,42(7):549-559.DOI:10.1007/s12272-019-01146-9. [32] Bai L,Zhou BS,Zhao YX.Dynamic changes in T-cell subsets and C-reactive protein after radiation therapy in lung cancer patients and correlation with symptomatic radiation pneumonitis treated with steroid therapy[J].Cancer Manag Res,2019,11:7925-7931.DOI:10.2147/CMAR.S209286. [33] Lee YH,Choi HS,Jeong H,et al.Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy[J].Clin Respir J,2018,12(3):1264-1273.DOI:10.1111/crj.12660. [34] Pan WY,Bian C,Zou GL,et al.Combing NLR,V20 and mean lung dose to predict radiation induced lung injury in patients with lung cancer treated with intensity modulated radiation therapy and chemotherapy[J].Oncotarget,2017,8(46):81387-81393.DOI:10.18632/oncotarget.19032. [35] Schoenfeld JD,Nishino M,Severgnini M,et al.Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical,radiologic and circulating biomarker features[J].J Immunother Cancer,2019,7(1):112.DOI:10.1186/s40425-019-0583-3. [36] Lu Z,Ma Y,Zhang S,et al.Transforming growth factor-β1small interfering RNA inhibits growth of human embryonic lung fibroblast HFL-I cells in vitro and defends against radiation-induced lung injury in vivo[J].Mol Med Rep,2015,11(3):2055-2061.DOI:10.3892/mmr.2014.2923. [37] Liu Y,Xia T,Zhang W,et al.Variations of circulating endothelial progenitor cells and transforming growth factor-beta-1(TGF-β1) during thoracic radiotherapy are predictive for radiation pneumonitis[J].Radiat Oncol,2013,8:189.DOI:10.1186/1748-717X-8-189. [38] Liu G,Li Q,Yang X,et al.The correlation between serum contents of TGF-β1 and IL-6 and acute radiation pneumonitis in patients with lung cancer[J].J Acu Dis,2016,5(4):333-336.DOI:10.1016/j.joad.2016.05.003. [39] Kim JY,Kim YS,Kim YK,et al.The TGF-beta1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients[J].Radiat Oncol,2009,4:59.DOI:10.1186/1748-717X-4-59. [40] Lu SL,Hsu FM,Tsai CL,et al.Serum transforming growth factor-β1 change after neoadjuvant chemoradiation therapy is associated with postoperative pulmonary complications in esophageal cancer patients undergoing combined modality therapy[J].Int J Radiat Oncol Biol Phys,2015,93(5):1023-1031.DOI:10.1016/j.ijrobp.2015.08.035. [41] Sohn SH,Lee JM,Park S,et al.The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice[J].Environ Toxicol Pharmacol,2015,39(2):917-926.DOI:10.1016/j.etap.2015.02.019. [42] Wang S,Stenmark MH,Chen J,et al.A novel radiation pneumonitis predictive model with MLD and IL-8 for non-small cell lung cancer patients[J].Int J Radiat Oncol Biol Phys,2015,93(3):S153-S153.DOI:10.1016/j.ijrobp.2015.07.363. [43] Wang S,Campbell J,Stenmark MH,et al.Plasma levels of IL-8 and TGF-β1 predict radiation-induced lung toxicity in non-small cell lung cancer:a validation study[J].Int J Radiat Oncol Biol Phys,2017,98(3):615-621.DOI:10.1016/j.ijrobp.2017.03.011. [44] Gandhi KA,Goda JS,Gandhi VV,et al.Oral aDministration of 3,3′-diselenodipropionic acid prevents thoracic radiation induced pneumonitis in mice by suppressing NF-kB/IL-17/G-CSF/neutrophil axis[J].Free Radic Biol Med,2019,145(1):8-19.DOI:10.1016/j.freeradbiomed.2019.09.009. [45] Wang BZ,Wang LP,Han H,et al.Interleukin-17A antagonist attenuates radiation-induced lung injuries in mice[J].Exp Lung Res,2014,40(2):77-85.DOI:10.3109/01902148.2013.872210. [46] 陈安艳,王连青,申振涛,等.血清IL-6、IL-10、IL-17及IL-33水平与食管癌患者放射性肺损伤关系的研究[J].癌症进展,2019,17(23):2825-2829.DOI:10.11877/j.issn.1672-1535.2019.17.23.24. Chen AY,Wang LQ,Shen ZT,et al.Study of relationship between the serum levels of IL-6,IL-10,IL-17,IL-33 and radiation induced lung injury in patients with esophageal cancer[J].Oncol Prog,2019,17(23):2825-2829.DOI:10.11877/j.issn.1672-1535.2019.17.23.24. [47] Guo L,Ding G,Xu W,et al.Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging[J].Exp Ther Med,2019,17(1):244-250.DOI:10.3892/etm.2018.6936. [48] Vervloet LA,Camargos PA,Soares DR,et al.Clinical,radiographic and hematological characteristics of Mycoplasma pneumoniae pneumonia[J].J Pediatr (Rio J),2010,86(6):480-487.DOI:10.2223/JPED.2044. [49] Sanuki N,Ono A,Komatsu E,et al.Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy[J].J Radiat Res,2012,53(1):110-116.DOI:10.1269/jrr.110142. [50] 吴侃,杨邵瑜,徐晓,等.C反应蛋白联合中性粒细胞数预测容积旋转调强放疗后急性放射性肺炎的临床研究[J].实用肿瘤杂志,2018,33(5):450-454.DOI:10.13267/j.cnki.syzlzz.2018.05.014. Wu K,Yang SY,Xu X,et al.C-reactive protein combined with neutrophil counts in predicting acute radiation pneumonitis after volumetric modulated arc therapy[J].J Pract Oncol,2018,33(5):450-454.DOI:10.13267/j.cnki.syzlzz.2018.05.014. [51] Torre-Bouscoulet L,Mu?Boz-Monta?Bo WR,Martínez-Brise?Bo D,et al.Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung cancer[J].Respir Res,2018,19(1):72.DOI:10.1186/s12931-018-0775-2. [52] 付金平,陈惠,晋发,等.胸部放疗中肺功能变化与放射性肺炎的相关性研究[J].癌症进展,2017,15(12):1470-1472.DOI:10.11877/j.issn.1672-1535.2017.15.12.30. Fu JP,Chen H,Jin F,et al.Correlation between the change of pulmonary function and radiation Correlation between the change of pulmonary function and radiation pneumonitis during chest radiotherapy[J].Oncol Prog,2017,15(12):1470-1472.DOI:10.11877/j.issn.1672-1535.2017.15.12.30. [53] Zhou Y,Yan T,Zhou X,et al.Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy:impact of pre-treatment pulmonary function parameters[J].Strahlenther Onkol,2020,196(6):505-514.DOI:10.1007/s00066-019-01552-4. [54] Ferro AC,Han P,Voong R,et al.Pulmonary function trends following modern radiation therapy:association of CTC provider assessment with subacute and late PFT changes[J].Int J Radiat Oncol Biol Phys,2018,102(3):e681-e682.DOI:10.1016/j.ijrobp.2018.07.1839. [55] 陆琼,毛佳蕾,黄辰羊,等.FeNO预测肺癌患者放射性肺炎的临床价值[J].现代肿瘤医学,2020,28(6):1005-1011.DOI:10.3969/j.issn.1672-4992.2020.06.029. Lu Q,Mao JL,Huang CY,et al.Clinical value of FeNO in predicting radiation pneumonia in lung cancer patients[J].Mod Oncol,2020,28(6):1005-1011.DOI:10.3969/j.issn.1672-4992.2020.06.029. [56] 李同源,陈鲁青,王晓红,等.放疗前肺功能检测FEV1%、FEV1/FVC、DLCO%指标对预测老年非小细胞肺癌患者放射性肺炎方面的价值探究[J].中国实用医药,2019,14(20):8-10.DOI:10.14163/j.cnki.11-5547/r.2019.20.004. Li TY,Chen LQ,Wang XH,et al.Investigation on value of pulmonary function testing of FEV1%,FEV1/FVC and DLCO% in predicting radiation pneumonia of elderly patients with non-small cell lung cancer before radiotherapy[J].Chin Prac Med,2019,14(20):8-10.DOI:10.14163/j.cnki.11-5547/r.2019.20.004. [57] 王天昶,冯杏,王浩,等.放疗前肺功能参数对非小细胞肺癌放射性肺炎的预测价值[J].实用癌症杂志,2016,31(4):581-584.DOI:10.3969/j.issn.1001-5930.2016.04.019. Wang TC,Feng X,Wang H,et al.Predictive value of lung function parameters on radiation pneumonitis in patients with non-small-cell lung cancer[J].Pract J Cancer,2016,31(4):581-584.DOI:10.3969/j.issn.1001-5930.2016.04.019. [58] Wang L,Liang S,Li C,et al.A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiation therapy[J].Int J Radiat Oncol Biol Phys,2019,105(5):1074-1085.DOI:10.1016/j.ijrobp.2019.08.024.
2021, Vol. 30 
